

ASX RELEASE

23 July 2018

European Patent Granted for Innate's drug candidate AMP-886

Innate Immunotherapeutics Limited (ASX: IIL) is pleased to announce the European Patent Office (EPO) decision to grant a patent with respect to the Company's drug candidate AMP-886. Importantly, the patent claims the composition of AMP-886 and also processes for the preparation of the compound or pharmaceutical compositions containing the compound. The patent also claims the use of AMP-886 to treat proliferative diseases such as cancer and idiopathic pulmonary fibrosis.

The European patent application with respect to the Company's lead drug candidate AMP-945 is at an advanced stage and the Company anticipates a favourable outcome for this application in the coming months.

Both AMP-886 and AMP945 are already protected by separate issued patents in the United States, Japan, China and Australia, with applications also pending in other territories. These patents claim both the composition of the compounds as well as their use in proliferative diseases. Proliferative diseases refers to a broad range of diseases where the excessive proliferation of cells contributes significantly to the development of the disease.

Arising from the same initial development program, AMP-886 and AMP-945 have differentiating characteristics which make them highly promising candidates in multiple and distinct therapeutic settings.

AMP-945 is a highly selective inhibitor of focal adhesion kinase (FAK). This potentially makes AMP-945 a strong candidate for combination use in the immuno-oncology setting, especially in fibrotic cancers such as pancreatic cancer, as well as standalone use in fibrotic diseases such as idiopathic pulmonary fibrosis.

AMP-886 is a triple kinase inhibitor targeting not only FAK but also tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor 3 (VEGFR3). This potentially makes AMP-886 a unique candidate, in combination with certain chemotherapeutics, for the treatment of cancers that are resistant to immuno-oncology treatment strategies or existing standard of care treatment regimes.

Innate Chairman Dr Warwick Tong, formerly CEO of the Australian Cancer Therapeutics CRC which developed both compounds, said "the European patent grant is the latest brick in what has fast become a very strong wall of IP protection around these exciting assets. Our IP position is providing a solid platform to underpin the clinical development of both '886 and '945, and will be vital to building commercial partnerships around these assets".

- End -

For Further Information:

Simon Wilkinson, Managing Director and CEO

Email: simon@innateimmuno.com

Suite 226, 55 Flemington Road, North Melbourne, VIC 3051

Email info@innateimmuno.com

www.innateimmuno.com